Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

Lurje, Georg; Schiesser, Marc; Claudius, Andreas; Schneider, Paul M.

doi:10.1155/2010/392652

Cited by 35 publications

(33 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, a variety of methods for detecting CTC from peripheral blood are available, including flow cytometry, immunomagnetic separation, CTC microchip technology, PCR-based approaches and the FDA-approved and widely accepted CellSearch® [19]. All of these techniques have distinct advantages and limitations.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas

et al. 2015

View full text Add to dashboard Cite

Objective: We aimed to assess the prognostic value of circulating tumor cells (CTC) in patients with advanced gastric and gastroesophageal adenocarcinomas. Methods: The presence of CTC was evaluated in 62 patients with advanced gastric and gastroesophageal adenocarcinomas before systemic therapy and at follow-up through immunomagnetic enrichment for mucin 1- and epithelial cell adhesion molecule (EpCAM)-positive cells, followed by real-time RT-PCR of the tumor-associated genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5. Results: The patients were stratified into groups according to CTC detection (CTC negative: with all marker genes negative; CTC positive: with at least 1 of the marker genes positive). Patients who were CTC positive at baseline had a significantly shorter median progression-free survival (PFS; 3.5 months, 95% CI: 2.9-4.2) and overall survival (OS; 5.8 months, 95% CI: 4.5-7.0) than patients lacking CTC (PFS 10.7 months, 95% CI: 6.9-14.4, p < 0.001; OS 13.3 months, 95% CI: 8.0-18.6, p = 0.003). Alterations in the marker profile during the course of chemotherapy were not predictive of clinical outcome or response to therapy. Yet, a favorable clinical response depended significantly on CTC negativity (p = 0.03). Conclusion: Our data suggest that the presence of CTC is a major predictor of outcome in patients with gastric and gastroesophageal malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This report indicates a prognostic utility of CTCs evaluation in EC. Furthermore, qPCR of tumor-specific mRNA is characterized by higher sensitivity in comparison to protein-based methods and usually ranges within a detection range of 1 to 10 tumor cells among 10 6 -10 7 blood mononuclear cells [11]. Nevertheless, the high sensitivity of qPCR is problematic when false-positive results are encountered, as it is the case with sample contamination (genomic DNA versus cDNA) and illegitimate transcription (low-level nonspecific transcription of certain genes) [11].…”

Section: Discussionmentioning

confidence: 99%

Cultivation of circulating tumor cells in esophageal cancer

Bobek

Matkowski²,

Gürlich³

et al. 2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The presence of circulating tumor cells (CTCs) in patients with metastatic carcinoma is generally associated with poor clinical outcome. There have been many investigations showing a possible use of CTCs as minimally invasive predictive and prognostic biomarker in cancer medicine. In this report a size-based method (MetaCell ® ) for quick and easy enrichment and cultivation of CTCs is presented to enable possible CTCs use in esophageal cancer (EC) management. In total, 43 patients with diagnosed EC, 20 with adenocarcinoma (Adeno Ca) and 23 with squamous cell carcinoma (SCC), were enrolled into the adaptive prospective-like study. All the patients were candidates for surgery. The CTCs were detected in 27 patients (62.8%), with a higher rate in adenocarcinoma (75%) than SCC (52%). Finally, there were 26 patients with resectable tumors exhibiting CTCs-positivity in 69.2% and 17 patients with non-resectable tumors with 41.7% CTCs-positivity. Interestingly, in the patients undergoing neoadjuvant therapy, the CTCs were detected at time of surgery in 55.5% (10/18). The overall size-based filtration approach enabled to isolate viable CTCs and evaluate to their cytomorphological features by means of vital fluorescent staining. The CTCs were cultured in vitro for further downstream applications including immunohistochemical analysis. This is the first report of the successful culturing of esophageal cancer CTCs. The detection of CTCs presence could help in the future to guide timing of surgical treatment in

show abstract

“…It was also the second highest cause of cancer death with 738,000 deaths (approximately 10 % of total deaths) in 2008 [1,2]. The high mortality of GC is primarily due to the fact that most patients have advanced disease stage III or IV at the time of diagnosis and cannot be cured with currently available therapies [3]. The 5-year survival rate of GC patients reaches almost 90 % in the cancer's early stages (I and II), but this rate reduces to less than 5 % in its advanced stages (III and IV) [4].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of circulating microRNAs for gastric cancer in Asian populations: a meta-analysis

et al. 2014

View full text Add to dashboard Cite

Gastric cancer (GC) accounts for one of the highest mortality worldwide and particularly in East Asia. Many studies have reported on the potential value of microRNAs (miRNAs) detection for diagnosing GC, but their results have proven inconclusive. The present meta-analysis was conducted to assess the diagnostic value of circulating miRNAs for GC diagnosis. A literature search was carried out in databases (PubMed, Embase, Web of Science, The Cochrane Library, and CNKI) and other sources using combinations of keywords relating to GC, miRNAs, and diagnosis. The values of sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR) reported in individual studies were pooled using random-effects models. Potential sources of heterogeneity were assessed with subgroup and meta-regression analyses. The summary receiver operating characteristic (SROC) curve and the area under the curve (AUC) were used to assess the diagnosis accuracy of miRNAs. This meta-analysis included 1,279 patients with GC and 954 healthy controls from 20 publications. The pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.78 (95 % CI: 0.73-0.81), 0.80 (95 % CI: 0.76-0.84), 4.0 (95 % CI: 3.1-6.0), 0.28 (95 % CI: 0.23-0.34), 14 (95 % CI: 10-21), and 0.86 (95 % CI: 0.83-0.89), respectively. Subgroup analyses showed that early stages (I and II) GC were more easily detected than later stages and that multiple miRNAs assays were more accurate than single miRNA assays. Our meta-analysis suggests that miRNAs have a high diagnostic value for GC, especially in its early stages (I and II). In addition, multiple miRNAs assays have a better diagnosis value than single miRNA assays. In conclusion, circulating miRNAs might be used as noninvasive biomarkers for the confirmation of GC detection in Asian populations.

show abstract

Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

Cited by 35 publications

References 67 publications

Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas

Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas

Cultivation of circulating tumor cells in esophageal cancer

Diagnostic value of circulating microRNAs for gastric cancer in Asian populations: a meta-analysis

Contact Info

Product

Resources

About